Physician profile
Nalini Samuel
NPI 1437241122
$6,221.05
in general payments reported to CMS, 2019-2025
43 companies · $976 in 2025
The $976 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $96.24 · 2021: $1,073 · 2022: $986 · 2023: $978 · 2024: $1,315 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,268.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,645.10 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Emd Serono, INC. | $673.25 | 2019-2025 | Mavenclad, Mavenclad |
| Neurelis, INC. | $409.04 | 2021-2025 | Valtoco |
| Biogen, INC. | $338.86 | 2019-2025 | Vumerity, Tysabri |
| Abbvie INC. | $288.57 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $257.79 | 2019-2020 | |
| Eisai INC. | $255.21 | 2019-2025 | |
| Genzyme Corporation | $214.08 | 2019-2022 | |
| Celgene Corporation | $210.19 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $203.07 | 2019-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $155.31 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $132.53 | 2019-2024 | Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $114.91 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $106.61 | 2019-2022 | |
| Lilly USA, LLC | $94.83 | 2021-2023 | Emgality, Reyvow, Amyvid |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalini Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.